0000899243-21-014278.txt : 20210331
0000899243-21-014278.hdr.sgml : 20210331
20210331201230
ACCESSION NUMBER: 0000899243-21-014278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210329
FILED AS OF DATE: 20210331
DATE AS OF CHANGE: 20210331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krieg Arthur M
CENTRAL INDEX KEY: 0001335659
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 21795479
MAIL ADDRESS:
STREET 1: C/O CHECKMATE PHARMACEUTICALS, INC.
STREET 2: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001651431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364813934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 978-503-2124
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-29
0
0001651431
Checkmate Pharmaceuticals, Inc.
CMPI
0001335659
Krieg Arthur M
C/O CHECKMATE PHARMACEUTICALS, INC.
245 MAIN STREET, 2ND FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2021-03-29
4
P
0
17468
10.94
A
764179
D
Common Stock
2021-03-29
4
P
0
15752
11.40
A
779931
D
Common Stock
68457
I
See footnote
Common Stock
68457
I
See footnote
Common Stock
68457
I
See footnote
The price reported in column 4 is a weighted average price. Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, these shares were purchased in multiple transactions, at prices ranging from $10.65 to $11.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported in column 4 is a weighted average price. Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person, these shares were purchased in multiple transactions, at prices ranging from $11.22 to $12.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The shares are held by an irrevocable trust for the Reporting Person's child. The Reporting Person serves as trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Kleem Chaudhary, attorney-in-fact
2021-03-31